Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Payables (2016 - 2025)

Historic Payables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $10.1 million.

  • Viridian Therapeutics, Inc.\DE's Payables rose 5877.25% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 5877.25%. This contributed to the annual value of $2.1 million for FY2024, which is 428.76% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Payables of $10.1 million as of Q3 2025, which was up 5877.25% from $8.5 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Payables high stood at $14.2 million for Q4 2022, and its period low was $2.1 million during Q4 2024.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's Payables averaged around $5.2 million, with its median value being $3.7 million (2023).
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Payables skyrocketed by 51116.36% in 2022, and later tumbled by 8427.01% in 2023.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Payables stood at $2.3 million in 2021, then surged by 511.16% to $14.2 million in 2022, then crashed by 84.27% to $2.2 million in 2023, then dropped by 4.29% to $2.1 million in 2024, then skyrocketed by 369.58% to $10.1 million in 2025.
  • Its last three reported values are $10.1 million in Q3 2025, $8.5 million for Q2 2025, and $3.9 million during Q1 2025.